H
Howard A. Burris
Researcher at Sarah Cannon Research Institute
Publications - 593
Citations - 40779
Howard A. Burris is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 80, co-authored 568 publications receiving 34783 citations. Previous affiliations of Howard A. Burris include American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris,Carla Kurkjian,Carla Kurkjian,Lowell L. Hart,Shubham Pant,Shubham Pant,Shubham Pant,Patrick Murphy,Suzanne F. Jones,Rachel Neuwirth,Chirag Patel,F. Zohren,J. R. Infante +12 more
TL;DR: TAK-228 demonstrated a safety profile consistent with other TORC inhibitors and promising preliminary antitumor activity in a range of tumor types and support further investigation of TAK-228 in combination with other agents including paclitaxel, with/without trastuzumab, in patients with advanced solid tumors.
Journal ArticleDOI
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
Howard A. Burris,Afshin Dowlati,Rebecca A. Moss,Jeffrey R. Infante,Suzanne F. Jones,David R. Spigel,Kelly Levinson,Diana Lindquist,Shelby D. Gainer,Mohammed M. Dar,A. Benjamin Suttle,Howard A. Ball,Antoinette R. Tan +12 more
TL;DR: The maximum-tolerated regimen of daily pazopanib in combination with paclitaxel 175 mg/m2 and carboplatin [dosed at area under the curve (AUC) 5 or 6] given every 21 days in patients with advanced solid tumors was evaluated.
Journal ArticleDOI
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
Dan Lu,Amita Joshi,Bei Wang,Steve Olsen,Joo-Hee Yi,Ian E. Krop,Howard A. Burris,Sandhya Girish +7 more
TL;DR: This semi-mechanistic integrated model links T-DM1 conjugate and total trastuzumab pharmacokinetic data, and supports the inclusion of both proteolytic degradation and deconjugation as clearance pathways in the hypothetical T- DM1 catabolism scheme.
Journal ArticleDOI
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer☆☆☆
David R. Spigel,F. Anthony Greco,Mark S. Rubin,Dianna Shipley,D. S. Thompson,Eric T. Lubiner,Janice F. Eakle,Raven Quinn,Howard A. Burris,John D. Hainsworth +9 more
TL;DR: This phase II trial provides support for further study of sunitinib maintenance therapy following platinum-doublet chemotherapy in patients with ES-SCLC, and a randomized trial would be appropriate to assess sunit inib's impact following chemotherapy.
Journal ArticleDOI
Phase 1 dose escalation of XMT-1522, a novel HER2-targeting antibody-drug conjugate (ADC), in patients (pts) with HER2-expressing breast, lung and gastric tumors.
Erika Hamilton,Minal A. Barve,Aditya Bardia,Muralidhar Beeram,Johanna C. Bendell,Rebecca Mosher,Hailman Eric P,Donald A. Bergstrom,Howard A. Burris,Hatem Soliman +9 more
TL;DR: XMT-1522 is comprised of 10-15 molecules of the payload AF-HPA, an auristatin-derivative with two-step intra-tumor metabolism intended to optimize therapeutic index, conjugated to a drug conjugation platform.